Experimental study on anti-ras gene product therapy in pancreatic carcinoma
Project/Area Number |
04807048
|
Research Category |
Grant-in-Aid for General Scientific Research (C)
|
Allocation Type | Single-year Grants |
Research Field |
Gastroenterology
|
Research Institution | Asahikawa Medical College |
Principal Investigator |
OBARA Takeshi Asahikawa Medical College Departmet of Internal Medicine III,Associate Professor, 医学部, 助手 (60194627)
|
Project Period (FY) |
1992 – 1994
|
Project Status |
Completed (Fiscal Year 1994)
|
Budget Amount *help |
¥2,000,000 (Direct Cost: ¥2,000,000)
Fiscal Year 1994: ¥400,000 (Direct Cost: ¥400,000)
Fiscal Year 1993: ¥400,000 (Direct Cost: ¥400,000)
Fiscal Year 1992: ¥1,200,000 (Direct Cost: ¥1,200,000)
|
Keywords | pancreatic carcinoma / oncogene / chemotherapy |
Research Abstract |
1) Cytotoxic effect of simvastatin, HMG-CoA reductase inhibitor, on human pancreatic adenocarcinoma cells containing mutant ras gene. The dose-dependent (0.1-100mug/ml) cytotoxicity of simvastatin (SV) to human (MIA PaCa-2, Panc-1, HPC-3, HPC-4, PK-1, PK-9) and hamster (T2) pancreatic carcinoma cell lines was determined by MTT assay. The concentration of SV necessary to achieve 50% cytotoxicity was about 10mug/ml and at this concentration of SV,DNA synthesis assayd in terms of [^3H] thymidine uptake, isoprenylation of p21^<ras> examined by Western botting, and cell progression from G1 to S prase of the cell cycle analyzed by flow cytometry were all inhibited. 2) cytotoxic effect of gliotoxin, a farnesyl protein transferase (FPTase) on H-ras transformed fibroblast. Gliotoxin (GT) inhibited farnesylation of p21^<ras> dose-dependently (0.6-10mug/ml) within 24hr by Western blotting. The concentration necessary to achieve 50% cytotoxity was about 0.3mug/ml, determined by MTT assay for 72hr incubation. DNA fragmentation was observed by agalose get at a cytotoxic dose of GT,indicating that the mode of cell death is apoptosis. In conclusion, these results suggest that above compound are possibly useful as anti-tumor agents for the carcinoma cells containing mutant ras gene.
|
Report
(4 results)
Research Products
(6 results)